Benign essential blepharospasm: epidemiology, clinical manifestations, pathophysiology, botulinum toxin therapy
Blepharospasm (BPS) is a variant of focal dystonia manifested by involuntary eyelid spasms with eye closure and/or increased spontaneous blinking. Along with motor symptoms, this condition is characterized by sensory, affective, and cognitive disorders. Patients with BPS are found to have changes in...
Main Author: | |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2021-02-01
|
Series: | Nevrologiâ, Nejropsihiatriâ, Psihosomatika |
Subjects: | |
Online Access: | https://nnp.ima-press.net/nnp/article/view/1521 |
id |
doaj-a8e46509a65f47faa41d56f866f7e168 |
---|---|
record_format |
Article |
spelling |
doaj-a8e46509a65f47faa41d56f866f7e1682021-07-29T08:58:42ZrusIMA-PRESS LLCNevrologiâ, Nejropsihiatriâ, Psihosomatika2074-27112310-13422021-02-0113111912510.14412/2074-2711-2021-1-119-1251103Benign essential blepharospasm: epidemiology, clinical manifestations, pathophysiology, botulinum toxin therapyZ. A. Zalyalova0Kazan State Medical University, Ministry of Health of Russia; Republican Consultative and Diagnostic Center for Extrapyramidal Pathology and Botulinum Toxin Therapy, Ministry of Health of the Republic of TatarstanBlepharospasm (BPS) is a variant of focal dystonia manifested by involuntary eyelid spasms with eye closure and/or increased spontaneous blinking. Along with motor symptoms, this condition is characterized by sensory, affective, and cognitive disorders. Patients with BPS are found to have changes in the basal ganglia, cerebellum, primary/secondary sensorimotor and visual areas according to functional magnetic resonance imaging. This may reflect the involvement of above regions in suppressing defective movement and sensorimotor disintegration. Botulinum toxin therapy is the most effective treatment for BPS. The advantage of Xeomin® that does not contain complexing proteins, is characterized by a low probability of antibody production, is the ability to vary between-injection intervals. Probably, botulinum toxin therapy has a pathogenetic and modifying impact on BPS.https://nnp.ima-press.net/nnp/article/view/1521dystoniablepharospasmsensor trickseyelid opening apraxiaphotophobiamusculus orbicularis oculisensorimotor disintegrationwink reflexfunctional magnetic resonance imagingbotulinum toxin therapyincobotulinotoxin a |
collection |
DOAJ |
language |
Russian |
format |
Article |
sources |
DOAJ |
author |
Z. A. Zalyalova |
spellingShingle |
Z. A. Zalyalova Benign essential blepharospasm: epidemiology, clinical manifestations, pathophysiology, botulinum toxin therapy Nevrologiâ, Nejropsihiatriâ, Psihosomatika dystonia blepharospasm sensor tricks eyelid opening apraxia photophobia musculus orbicularis oculi sensorimotor disintegration wink reflex functional magnetic resonance imaging botulinum toxin therapy incobotulinotoxin a |
author_facet |
Z. A. Zalyalova |
author_sort |
Z. A. Zalyalova |
title |
Benign essential blepharospasm: epidemiology, clinical manifestations, pathophysiology, botulinum toxin therapy |
title_short |
Benign essential blepharospasm: epidemiology, clinical manifestations, pathophysiology, botulinum toxin therapy |
title_full |
Benign essential blepharospasm: epidemiology, clinical manifestations, pathophysiology, botulinum toxin therapy |
title_fullStr |
Benign essential blepharospasm: epidemiology, clinical manifestations, pathophysiology, botulinum toxin therapy |
title_full_unstemmed |
Benign essential blepharospasm: epidemiology, clinical manifestations, pathophysiology, botulinum toxin therapy |
title_sort |
benign essential blepharospasm: epidemiology, clinical manifestations, pathophysiology, botulinum toxin therapy |
publisher |
IMA-PRESS LLC |
series |
Nevrologiâ, Nejropsihiatriâ, Psihosomatika |
issn |
2074-2711 2310-1342 |
publishDate |
2021-02-01 |
description |
Blepharospasm (BPS) is a variant of focal dystonia manifested by involuntary eyelid spasms with eye closure and/or increased spontaneous blinking. Along with motor symptoms, this condition is characterized by sensory, affective, and cognitive disorders. Patients with BPS are found to have changes in the basal ganglia, cerebellum, primary/secondary sensorimotor and visual areas according to functional magnetic resonance imaging. This may reflect the involvement of above regions in suppressing defective movement and sensorimotor disintegration. Botulinum toxin therapy is the most effective treatment for BPS. The advantage of Xeomin® that does not contain complexing proteins, is characterized by a low probability of antibody production, is the ability to vary between-injection intervals. Probably, botulinum toxin therapy has a pathogenetic and modifying impact on BPS. |
topic |
dystonia blepharospasm sensor tricks eyelid opening apraxia photophobia musculus orbicularis oculi sensorimotor disintegration wink reflex functional magnetic resonance imaging botulinum toxin therapy incobotulinotoxin a |
url |
https://nnp.ima-press.net/nnp/article/view/1521 |
work_keys_str_mv |
AT zazalyalova benignessentialblepharospasmepidemiologyclinicalmanifestationspathophysiologybotulinumtoxintherapy |
_version_ |
1721250529110130688 |